MDT

83.9

-4.72%↓

VEEV

212.46

-4.94%↓

104.34

-6.4%↓

HQY

77.08

-8.9%↓

PDCO

30.92

-1.09%↓

MDT

83.9

-4.72%↓

VEEV

212.46

-4.94%↓

104.34

-6.4%↓

HQY

77.08

-8.9%↓

PDCO

30.92

-1.09%↓

MDT

83.9

-4.72%↓

VEEV

212.46

-4.94%↓

104.34

-6.4%↓

HQY

77.08

-8.9%↓

PDCO

30.92

-1.09%↓

MDT

83.9

-4.72%↓

VEEV

212.46

-4.94%↓

104.34

-6.4%↓

HQY

77.08

-8.9%↓

PDCO

30.92

-1.09%↓

MDT

83.9

-4.72%↓

VEEV

212.46

-4.94%↓

104.34

-6.4%↓

HQY

77.08

-8.9%↓

PDCO

30.92

-1.09%↓

Начало・Списък с акции・Haemonetics Corp

Haemonetics Corp

Отворен

СекторЗдравеопазване

60.76 -3.29

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

59.88

Максимум

62.87

Ключови измерители
By Trading Economics
Приходи	3.7M 37M
Продажби	3M 349M
P/E Средно за сектора	25.02 63.778
EPS	1.19
Марж на печалбата	10.757
Служители	3,657
EBITDA	-37M 59M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+55.43% upside

Дивиденти
By Dow Jones
Следващи печалби	8.05.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-359M 3.2B
Предишно отваряне	64.05
Предишно затваряне	60.76

Настроения в новините

By Acuity

50%

166 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

62.03 / 64.24 Подкрепа & съпротива

Haemonetics Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.04.2025 г., 23:04 ч. UTC

Топ новини

JPMorgan Raises Risk of U.S., Global Recession to 60%

3.04.2025 г., 22:40 ч. UTC

Значими двигатели на пазара

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3.04.2025 г., 22:18 ч. UTC

Придобивния, сливания и поглъщания

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3.04.2025 г., 18:51 ч. UTC

Придобивния, сливания и поглъщания

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

4.04.2025 г., 00:00 ч. UTC

Топ новини

Resistance Is Futile, Make a Deal: Trump's Tariff Message to the World -- WSJ

3.04.2025 г., 23:43 ч. UTC

Пазарно говорене

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3.04.2025 г., 23:41 ч. UTC

Пазарно говорене

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3.04.2025 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3.04.2025 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3.04.2025 г., 21:43 ч. UTC

Топ новини

Печалби

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3.04.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

3.04.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

3.04.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

3.04.2025 г., 20:43 ч. UTC

Пазарно говорене

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3.04.2025 г., 20:34 ч. UTC

Топ новини

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3.04.2025 г., 20:23 ч. UTC

Топ новини

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3.04.2025 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3.04.2025 г., 19:55 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

3.04.2025 г., 19:55 ч. UTC

Пазарно говорене

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3.04.2025 г., 19:21 ч. UTC

Пазарно говорене

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3.04.2025 г., 19:15 ч. UTC

Пазарно говорене

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3.04.2025 г., 18:45 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

3.04.2025 г., 18:45 ч. UTC

Пазарно говорене

Gold Drops In Tariff Fallout -- Market Talk

3.04.2025 г., 18:39 ч. UTC

Пазарно говорене

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3.04.2025 г., 18:38 ч. UTC

Топ новини

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3.04.2025 г., 18:30 ч. UTC

Топ новини

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3.04.2025 г., 18:20 ч. UTC

Пазарно говорене

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3.04.2025 г., 18:18 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

3.04.2025 г., 18:17 ч. UTC

Пазарно говорене

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3.04.2025 г., 18:04 ч. UTC

Пазарно говорене

US Sees More Job Openings in Construction, Transportation -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Haemonetics Corp Прогноза

Ценова цел

By TipRanks

55.43% нагоре

12-месечна прогноза

Среден 96.71 USD 55.43%

Висок 115 USD

Нисък 68 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за Haemonetics Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

9 ratings

Купи

Задържане

Продай

Според 9 анализатори, дали борсови рейтинги на Haemonetics Corp през последните 3 месеца.

Техническа оценка

By Trading Central

62.03 / 64.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Настроение

By Acuity

166 / 386 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Haemonetics Corp

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.